Osteoporosis Pipeline Breakthroughs Report 2025: New Clinical Milestones and Strategic Updates Transforming Disease Management

DelveInsight's, "Osteoporosis Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Osteoporosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Osteoporosis Pipeline? Click here to explore the therapies and trials making headlines @ Osteoporosis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Osteoporosis Pipeline Report

* In October 2025, Amgen conducted a phase 4 Single Arm Open Label Study for the Efficacy and Safety of Prolia in Treatment of Male Subjects With Osteoporosis in Mainland China.
* DelveInsight's Osteoporosis Pipeline report depicts a robust space with 30+ active players working to develop 35+ pipeline therapies for Osteoporosis treatment.
* The leading Osteoporosis Companies such as mAbxience, Alvotech, Transcenta Holding, Suzhou Suncadia Biopharmaceuticals, GlycoNex, Cellatoz Therapeutics, Enzo Biochem, Surrozen and others.
* Promising Osteoporosis Therapies such as Prolia, Romosozumab, Zoledronic Acid, Teriparatide, MK-5442, Alendronate Sodium, Teriparatide (PF708), AK156, AAE581, Bazedoxifene Acetate (TSE-424), and others.

Want to know which companies are leading innovation in Osteoporosis? Dive into the full pipeline insights @ Osteoporosis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Osteoporosis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Osteoporosis Pipeline Report also highlights the unmet needs with respect to Osteoporosis.

Osteoporosis Overview

Osteoporosis is a bone disease that develops when bone mineral density and bone mass decreases, or when the quality or structure of bone changes. This can lead to a decrease in bone strength that can increase the risk of fractures (broken bones). Osteoporosis is a "silent" disease because a person typically do not have symptoms, and may not even know that they have the disease until they break a bone.

Osteoporosis Emerging Drugs

* AVT03: Alvotech

AVT03 is a human monoclonal antibody and a biosimilar candidate to Prolia and Xgeva (denosumab). Denosumab targets and binds with high affinity and specificity to the RANK ligand membrane protein, preventing the RANK ligand/RANK interaction from occurring, resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer-induced bone destruction. AVT03 is an investigational product and has not received regulatory approval in any country. Currently, the drug is in Phase III stage of its development for the treatment of osteoporosis.

* TST002: Transcenta Holding

TST002 (Blosozumab) is a humanized anti-sclerostin monoclonal antibody as a drug candidate for osteoporosis and other bone loss diseases. It has a dual effect possessing both anabolic and anti-resorptive effects, which stimulates bone formation and inhibits bone absorption, resulting in fast increase in bone mineral density and bone strength. Blocking sclerostin activity in human treated with anti-sclerostin antibody or with naturally occurring genetic deletion has been shown to be an effective approach in increasing bone mineral density (BMD) and reducing bone fracture. Currently, the drug is in Phase II stage of its clinical trial for the treatment of osteoporosis.

* Denosumab biosimilar: GlycoNex

GlycoNex, a Taiwanese biotech company, is developing a denosumab biosimilar called SPD8 for the treatment of osteoporosis. Denosumab is a fully human monoclonal antibody that inhibits receptor activator of nuclear factor kappa-B ligand (RANKL), a key regulator of osteoclast formation, function and survival. By blocking RANKL, denosumab reduces bone resorption and increases bone mineral density. GlycoNex recently reported positive results from a Phase I clinical trial of SPD8, which met its primary endpoint of pharmacokinetic equivalence to the reference product. Currently, the drug is in Phase II stage of its clinical trial for the treatment of osteoporosis.

If you're tracking ongoing Osteoporosis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Osteoporosis Treatment Drugs [https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Osteoporosis Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Osteoporosis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteoporosis Treatment.
* Osteoporosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Osteoporosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Osteoporosis market.

Osteoporosis Companies

mAbxience, Alvotech, Transcenta Holding, Suzhou Suncadia Biopharmaceuticals, GlycoNex, Cellatoz Therapeutics, Enzo Biochem, Surrozen and others.

Osteoporosis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Osteoporosis Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Stay ahead in Musculoskeletal Research - discover what's next for the Osteoporosis Treatment landscape in this detailed analysis @ Osteoporosis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Osteoporosis Pipeline Report

* Coverage- Global
* Osteoporosis Companies- mAbxience, Alvotech, Transcenta Holding, Suzhou Suncadia Biopharmaceuticals, GlycoNex, Cellatoz Therapeutics, Enzo Biochem, Surrozen and others.
* Osteoporosis Therapies- Prolia, Romosozumab, Zoledronic Acid, Teriparatide, MK-5442, Alendronate Sodium, Teriparatide (PF708), AK156, AAE581, Bazedoxifene Acetate (TSE-424), and others.
* Osteoporosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Osteoporosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Musculoskeletal Research - discover what's next for the Osteoporosis Treatment landscape in this detailed analysis @ Osteoporosis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Osteoporosis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Osteoporosis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* AVT03: Alvotech
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* TST002: Transcenta Holding
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Denosumab biosimilar: GlycoNex
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Osteoporosis Key Companies
* Osteoporosis Key Products
* Osteoporosis- Unmet Needs
* Osteoporosis- Market Drivers and Barriers
* Osteoporosis- Future Perspectives and Conclusion
* Osteoporosis Analyst Views
* Osteoporosis Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=osteoporosis-pipeline-breakthroughs-report-2025-new-clinical-milestones-and-strategic-updates-transforming-disease-management]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/osteoporosis-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.